1
Orville G Kolterman, Andrew A Young: Exendin agonist formulations and methods of administration thereof. Amylin Pharmaceuticals, Arnold & Porter, June 7, 2005: US06902744 (45 worldwide citation)

Novel exendin and exendin agonist compound formulations and dosages and methods of administration thereof are provided. These compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhi ...


2
Orville G Kolterman, Andrew A Young, Timothy J Rink, Kathleen Ann Keiting Brown: Methods for regulating gastrointestinal motility. Amylin Pharmaceuticals, Lyon & Lyon, September 5, 2000: US06114304 (33 worldwide citation)

Methods for treating conditions associated with elevated, inappropriate or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an amylin agonist alone or in conjunction with other anti-gastric emptying agents. Methods for reducing gastri ...


3
Orville G Kolterman, Robert G Thompson, John F Mullane: Treatment of type II diabetes mellitus with amylin agonists. Amylin Pharmaceuticals, Bradford J Duft, Lisa M McGeehan, July 9, 2002: US06417164 (15 worldwide citation)

Methods for treating non-insulin-taking Type II diabetes mellitus which comprise administering a therapeutically effective amount of an amylin agonist.


4
Orville G Kolterman, Robert G Thompson, John F Mullane: Treatment of Type II diabetes mellutis with amylin agonists. Amylin Pharmaceuticals, Lyon & Lyon, November 7, 2000: US06143718 (12 worldwide citation)

Methods for treating non-insulin-taking Type II diabetes mellitus which comprise administering a therapeutically effective amount of an amylin agonist.


5
Orville G Kolterman, Timothy J Rink: Methods for regulating gastrointestinal motility. Amylin Pharmaceuticals, August 18, 1998: US05795861 (10 worldwide citation)

Methods for treating conditions associated with elevated, inappropriate or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an amylin agonist alone or in conjunction with other anti-gastric emptying agents. Methods for reducing gastri ...


6
Orville G Kolterman, Andrew A Young, James J L Italien: Exendin analog formulations. Amylin Pharmaceuticals, July 15, 2008: US07399489 (9 worldwide citation)

Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided.


7
Orville G Kolterman, Andrew A Young, Timothy J Rink, Kathleen Ann Keating Brown: Methods for regulating gastrointestinal motility. Amylin Pharmaceuticals, August 19, 2003: US06608029 (5 worldwide citation)

Methods for treating conditions associated with elevated, inappropriate or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an amylin agonist alone or in conjunction with other anti-gastric emptying agents. Methods for reducing gastri ...


8

9
Bradford J Duft, Orville G Kolterman: Methods for treating obesity. Amylin Pharmaceuticals, March 22, 2011: US07910548

Methods for treating obesity are disclosed which comprise administration of a therapeutically effective amount of an amylin or an amylin agonist alone or in conjunction with another obesity relief agent.


10
Orville G Kolterman, Andrew A Young, Timothy J Rink, Kathleen Ann Keating Brown: Methods for regulating postprandial blood glucose. Amylin Pharmaceuticals, Intellectual Property Group Amylin Pharmaceuticals, August 5, 2008: US07407934

Methods for treating conditions associated with elevated, inappropriate or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an amylin agonist alone or in conjunction with other anti-gastric emptying agents. Methods for reducing gastri ...